

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1 (Original). Pantoprazole multiparticulates having reduced release under gastric conditions and fast release at neutral pH, wherein each of said multiparticulates comprises:

a spheroid core comprising pantoprazole or an enantiomer thereof, or a salt or hydrate thereof, at least one surfactant, at least one distintegrant, and about 1% to about 2% w/w water;

an enteric coat on the core, said enteric coat comprising a copolymer of methacrylic acid and methacrylates in the range of about 15 to about 45 % w/w of the spheroid core; and

wherein said multiparticulates have an average size of about 1mm in diameter.

2 (Original). The pantoprazole multiparticulates according to claim 1, further comprising a final seal coat on the enteric coat.

3 (Original). The pantoprazole multiparticulates according to claim 2, wherein the final seal coat comprises about 0.1 to 10 wt% of the multiparticle.

Claims 4 – 5. Cancelled.

6 (Original). The pantoprazole multiparticulates according to claim 4, wherein said initial seal coat is in the range of about 2 to 4 % w/w of the weight of the uncoated core.

Claims 7 – 9. Cancelled.

10. The pantoprazole multiparticulates according to claim 9, wherein the polysorbate is polysorbate 80.

Claim 11. Cancelled.

12 (Original). The pantoprazole multiparticulates according to claim 1, wherein the enteric coating comprises about 30% w/w of Eudragit L 30 D-55 coating, about 15% w/w talc, about 3% triethyl citrate and a pH adjuster; said amounts being by weight of the microparticulate..

Claims 13 – 16. Cancelled.

17 (Original). The pantoprazole multiparticulates according to claim 16, wherein the microcrystalline cellulose comprises about 25 to about 30% by weight of the core.

Cancel claim 18.

19 (Original). The pantoprazole multiparticulates according to claim 1, wherein the spheroid core consists essentially of:

pantoprazole sodium sesquihydrate	45 % w/w
microcrystalline cellulose	27 % w/w
polysorbate 80	5 % w/w
crospovidone	15 % w/w
hypromellose 2208	1 % w/w and
sodium carbonate	7 % w/w.

Cancel claims 20 – 23.

24 (Original). A method of producing a multiparticle formulation of pantoprazole, said method comprising the steps of:

producing a spheroid core comprising pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, a disintegrant, via extrusion and spheronization, said core containing about 1 to about 2% w/w water;

applying an initial seal coat to the spheroid core, said seal coat being about 1 % w/w to about 20 % w/w of the multiparticulate;

applying an enteric coating over the initial seal coat, said enteric coating comprising a copolymer of methacrylic acid and methacrylates in an amount that provides the multiparticulate with 15 to 45 % w/w dry enteric coating polymer; and

optionally applying a final seal coat to the enteric-coated spheroid core, said final seal coat being about 1 wt% of the multiparticulate;

wherein said multiparticulates have an average size of no greater than about 1mm in diameter.

25 (Original). The method according to claim 24, wherein the spheroid core is prepared by mixing the ingredients in a low shear mixer at low shear conditions at a range of about 25 rpm to 35 rpm.

26 (Original). The method according to claim 25, wherein the low shear conditions are 32 rpm.

Cancel claim 27.

28 (Original). The method according to claim 24, further comprising the step of applying an layer of talc in an amount of 0.05% w/w to 0.1% w/w of the multiparticulate.

29 (Original). The method according to claim 24, wherein the enteric coating is sprayed as a suspension onto the spheroid core.

Cancel claim 30.